Has Ryan Harris, MD received payments from drug or device companies?

Yes. Drug and device makers reported $57,904 in general payments to Ryan Harris, MD across 152 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ryan Harris, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ryan Harris, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ryan Harris, MD

Dermatology · Meridian, IDNPI 1952628745

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,627 of the $57,904 with a category attached, or 73.6%. E.r. Squibb & Sons, L.L.C. accounts for 63.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $37,147 and has fallen 98.7% since, to $491 in 2025. Among dermatology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,904in general payments, 2019–2025

Across 152 payments — averaging $380.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$37K
VYNE Pharmaceuticals Inc.$15K
Pfizer$4K
Johnson & Johnson$425
AbbVie$419
Sun Pharmaceutical Industries Inc.$193
plus $916 from 20 others

$699,109in research payments, 2019–2025

Across 166 payments — averaging $4211.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$213K
Pfizer$158K
Endo Pharmaceuticals Inc.$136K
E.r. Squibb & Sons, L.L.C.$111K
AbbVie$62K
Incyte Corporation$7K
plus $12K from 3 others

What the payments were for

Consulting fees$9002%
Speaking & faculty fees$42,62774%
Travel & lodging$9,68817%
Food & beverage$4,3187%
Education$3701%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	35	$36,706
VYNE Pharmaceuticals Inc.	19	$15,105
Pfizer	17	$4,140
Johnson & Johnson	12	$425
AbbVie	17	$419
Sun Pharmaceutical Industries Inc.	6	$193
Amgen	5	$120
Lilly USA, LLC	5	$110
Incyte Corporation	5	$78
Novartis	3	$67
Arcutis Biotherapeutics, Inc.	3	$56
Dermavant Sciences, Inc.	3	$53
Boehringer Ingelheim	2	$45
UCB, Inc.	3	$44
Merz North America, Inc.	2	$43
Galderma Laboratories, L.p.	2	$39
Sanofi	2	$38
Stemline Therapeutics Inc.	1	$37
Regeneron Healthcare Solutions, Inc.	1	$37
LEO Pharma Inc.	2	$32
Helsinn Therapeutics (U.S.), Inc.	2	$29
Mayne Pharma Commercial LLC	1	$21
AstraZeneca	1	$20
Urgo Medical North America, LLC	1	$18
Botanix SB Inc	1	$17
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Sotyktu$35,258
AMZEEQ$14,629
EUCRISA$1,190
Humira$115

How this compares

$57,904 in reported general payments places this provider in the 90th percentile of 52 dermatology providers in Idaho.

See all dermatology providers in Idaho →

Medicare billing

Part B allowed, 2024

$106,709

Medicare patients

272

Services billed

1,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	17	$114,049
Clobetasol Propionate	75	$4,041
Fluocinonide	46	$1,407
Ketoconazole	105	$1,361
Doxycycline Hyclate	17	$594
Triamcinolone Acetonide	71	$463
CiclopiroxCiclopirox Olamine	13	$127
Terbinafine Hcl	15	$95
Hydrocortisone	13	$76
Ciclopirox	11	$76

Paid to pharmacies, not to this prescriber.

Other dermatology in Meridian

Mark SchwendimanMeridian$9K
Kelsey FerrellMeridian$6K
Randall BurrMeridian$5K
Benjamin PerryMeridian$4K
Richard ThomasMeridian$4K
Gregory WellsMeridian$3K
Whitney VinsonMeridian$3K
Alan PittMeridian$2K
Emily BoozalisMeridian$2K
Ryan WellsMeridian$1K

See the full list for Idaho →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →